SCHEMBL13705346

SCHEMBL13705346

O=C(OCc1ccccc1)N1CCN[C@H](CCOc2cc(F)cc(C(F)(F)F)c2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
ENPP2 Q13822 2/20 0.38
ATXN2 Q99700 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
CYP2C19 P33261 1/20 0.37
PTGDR2 Q9Y5Y4 4/20 0.37
MEN1 O00255 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PDK1 Q15118 1/20 0.36
PDK2 Q15119 1/20 0.36
PDK3 Q15120 1/20 0.36
PDK4 Q16654 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13705345 0.95 CXCR4 (0.41) CXCR4SMN1; SMN2ENPP2ATXN2NPC1
SCHEMBL8118778 0.92 CXCR4 (0.43) CXCR4SMN1; SMN2ENPP2ATXN2NPC1
SCHEMBL4291606 0.85 SCN9A (0.38)
SCHEMBL4860535 0.84 SMN1; SMN2 (0.47) CXCR4SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL13340760 0.84 SMN1; SMN2 (0.47) CXCR4SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL4860543 0.84 SMN1; SMN2 (0.47) CXCR4SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL13705348 0.81 GRIN2B (0.44) CXCR4SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL8124047 0.81 GPR183 (0.43) CXCR4SMN1; SMN2ENPP2ATXN2NPC1
SCHEMBL8126494 0.80 CXCR4 (0.45) CXCR4SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL13705354 0.80 CXCR4 (0.43) CXCR4SMN1; SMN2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT CXCR4 3648/4885SMN1; SMN2 4811/4885ENPP2 3719/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT CXCR4 3648/4885SMN1; SMN2 4811/4885ENPP2 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.